Neem Biotech, a Wales-based R&D biotech working in the field of novel antimicrobial drug development, announced today that it will be presenting results of its ongoing development work into the impact of NX-AS-401, its lead candidate,on biofilms in chronic cystic fibrosis lung infections at the 15th European Cystic Fibrosis Basic Science Conference taking place from 21st to 24th March 2018 in LoutrakiKorinthias, Greece.
NX-AS-401 is a first-in-class biofilm-disrupting agent with potential for use as an adjunct to conventionally prescribed antibiotics that are used to treat chronic infections caused by biofilm-forming bacteria. These biofilms insulate the bacteria both against the effects of any antibiotics taken and the host’s immune system and contribute to the further development of antimicrobial resistance.
NX-AS-401 has shown promise as a quorum sensing inhibitor that disrupts Pseudomonas aeruginosa generated biofilm and reduces production of associated virulence factors that result in damage to lung tissue and diminish cystic fibrosis transmembrane conductance regulator (CFTR) function.Normal CFTR function regulates fluid movement across the epithelial cell membranes thereby ensuring adequate hydration of these membranes and optimal movement of mucosal secretions from the lungs. Deficits in CFTR functioning give rise to mucous accumulation in the lungs that, in turn, constitutes a breeding ground for opportunistic, biofilm-forming bacteria such as P.aeruginosa.
With its specific focus on broadening the understanding of the biology underlying cystic fibrosis and its various treatment regimes, this conference is well suited for Neem to share its findings around the biofilm disruption activity of NX-AS-401 on P. aeruginosa produced biofilms.
Neem will present details of NX-AS-401’s impact on in vitro biofilms in cystic fibrosis respiratory infections in poster 106 on Thursday 22nd March 2018.
Graham Dixon, Managing Director of Neem Biotech, said:
We are delighted to be able to present a snapshot of our development work into novel ways of counteracting biofilms. This is an exciting time for Neem as we continue our preparations to take NX-AS-401 to clinical trial.